Breaking News
Top News
-
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
-
Evercore Adjusts Fortrea Holdings Inc. (FTRE) Valuation Following Updated Near-Term Assumptions
-
Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision
-
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver
-
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value
-
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
-
Morgan Stanley Updates Bicycle Therapeutics plc (BCYC) Outlook Amid Pipeline Refocus
-
Evercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector Revisions
-
RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance
-
Kevin O’Leary got choked up sharing 4 investing rules his mom followed for 55 years to put two kids through college
-
Gold Heads For Fourth Weekly Gain
-
Wall Street indexes rally after Iran says Strait of Hormuz ‘completely open’
-
Logistics layoffs top 800 as contracts unwind across trucking, warehousing
-
Truist Adjusts Community Health Systems, Inc. (CYH) Outlook Within Broader Sector Update
-
Morgan Stanley and JPMorgan Say Buy the Netflix Dip: Is Wall Street Right to Ignore the Q2 Guidance Scare?
-
ServiceNow price target lowered to $140 from $185 at TD Cowen
-
Stifel Raises MasTec’s Price Target as Transmission Surveys Hit Record Highs: Is This Infrastructure Stock About to Break Out?
-
Netflix earnings fail to clear high bar as guidance, Hastings exit weigh on stock
-
Microsoft price target lowered to $540 from $610 at TD Cowen
-
Martin Shkreli Says Elizabeth Warren Shoots From The Hip And Is Wrong About Tesla, Disney And Palantir Paying Zero Taxes: ‘You Don’t Know Facts’
2026-02-05



































